The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
分析師的觀點：愛美醫療在8位專家眼中
The perception of Amicus...In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics (NASDAQ:FOLD), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，已有8位分析師爲Amicus Therapeutics（納斯達克：FOLD）發佈了評級，展示了從看好到看淡的各種觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級，展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $21.00, and a low estimate of $15.00. Observing a 3.8% increase, the current average has risen from the previous average price target of $16.86.
分析師通過其對12個月價格目標的評估提供更深入的見解，顯示平均目標爲17.5美元，最高估值爲21.00美元，最低估值爲15.00美元。觀察到3.8%的增長，當前平均數已從之前的16.86美元上升。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析：詳細分析
The perception of Amicus...
愛美醫療...
登入免費觀看全文
登入/註冊
熱門討論
中概股財報季火熱：驚喜盈利能否延續漲勢？
1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？
Moomoo News Global
03/04 23:26
中國兩會：會議前後股票價格變動的關鍵要點